Advance next-generation sequencing and precision medicine through rapid and high quality targeted sequencing
At Paragon Genomics, we develop and commercialize rapid, easy-to-use, ultra-high multiplex PCR-based target enrichment solutions for Next-Generation Sequencing (NGS). Our proprietary CleanPlex® background-removing technology enables NGS customers to develop targeted sequencing assays that are accurate, sensitive, and simple, yet cost effective. Our technology is applicable to many fast-growing NGS segments such as cancer research, liquid biopsy, biomarker discovery, genomics-guided breeding, companion diagnostics, and immunotherapy monitoring.
Who We Are
At Paragon Genomics, we are a passionate group dedicated to providing cutting-edge technologies and solutions for the global genomic research and application community. Our goal is to move precision medicine forward. The team is composed of industry veterans and academic experts who previously worked with well-known industry leading companies and institutions such as Affymetrix, Novartis, Applied Biosystems, Siemens Healthcare, Stanford and Harvard.
Paragon Genomics’ leadership team proudly graduated from the California Life Sciences Institute’s (CLSI) Spring 2016 FAST Advisory Program. We were also honored to be accepted into the renowned StartX Fall 2016 Accelerator Program.
Tao Chen, MBA
Co-Founder and CEO
Zhitong Liu, PhD
Co-Founder and CTO
Guoying Liu, PhD
R&D and Operations
Edward Jan, PhD
CEO, AYOXXA Biosystems GmbH
Jin Billy Li, PhD
Associate Professor, Stanford University
Joe Keegan, PhD
Director, Interpace Diagnostics